Objective:To investigate the effect of levosimendan combined with dual antiplatelet therapy on heart failure in elderly patients with ischemic cardiomyopathy and its effect on ventricular remodeling, serum growth stimulating gene 2 protein (sST2) and N-terminal pro-brain natriuretic peptide (NT-proBNP) levels.Methods:A total of 158 elderly patients with ischemic cardiomyopathy admitted to Yan 'an People 's Hospital from December 2021 to December 2023 were selected as the research objects. Under the principle of balanced and comparable baseline characteristics between groups, they were divided into observation group ( n=79) and control group ( n=79) by random number table method. The patients in the control group received dual antiplatelet and conventional treatment, and patients in the observation group were treated with levosimendan on the basis of the treatment plan of the control group. After treatment, the effective rate, left ventricular ejection fraction (LVEF), left ventricular end-diastolic volume (LVEDV), left ventricular end-systolic volume (LVESV), serum sST2 level, NT-proBNP level and the incidence of disease-related adverse reactions after treatment were compared between the two groups. Measurement data with normal distribution were expressed as xˉ± s, and the mean comparison between groups was performed by independent sample t test. Counting data were expressed as case(%), comparison between groups was performed by χ2 test. P<0.05 was considered statistically significant. Results:After treatment, the effective rate of the observation group was 97.47% (77/79), which was significantly higher than 82.28% (65/79) of the control group ( χ2=10.01, P=0.002); at the same time, the LVEF level of the observation group after intervention was (49.26±3.98)%, which was significantly higher than that of the control group (46.13±4.02)%, and the difference was statistically significant ( t=4.92, P<0.001), and the levels of LVEDV and LVESV in the observation group after intervention were (104.25±18.36)mL and (49.24±6.37)mL, respectively, which were significantly lower than (118.97±19.25)mL and (55.12±6.28)mL in the control group, and the differences were statistically significant ( t values were 4.92 and 5.84, respectively; all P<0.01). In addition, the levels of sST2 and NT-proBNP in the observation group after intervention were (37.25±15.48)μg/L and (825.37±86.24)ng/L, respectively, which were significantly lower than those in the control group (66.35±16.37)μg/L and (1136.24±121.75)ng/L, and the differences were statistically significant ( t values were 11.48 and 18.52, respectively; all P<0.001); the total incidence of adverse drug reactions in the observation group and the control group was 17.72% (14/79) and 18.90% (15/79), respectively, and the difference was not statistically significant ( χ2=0.04, P=0.837). Conclusion:The combination of levosimendan and dual antiplatelet therapy can effectively improve the efficacy of ischemic cardiomyopathy in heart failure, improve ventricular remodeling, and regulate sST2 and NT proBNP levels, with high application value.

Objective:To investigate the effect of levosimendan combined with dual antiplatelet therapy on heart failure in elderly patients with ischemic cardiomyopathy and its effect on ventricular remodeling, serum growth stimulating gene 2 protein (sST2) and N-terminal pro-brain natriuretic peptide (NT-proBNP) levels.Methods:A total of 158 elderly patients with ischemic cardiomyopathy admitted to Yan 'an People 's Hospital from December 2021 to December 2023 were selected as the research objects. Under the principle of balanced and comparable baseline characteristics between groups, they were divided into observation group ( n=79) and control group ( n=79) by random number table method. The patients in the control group received dual antiplatelet and conventional treatment, and patients in the observation group were treated with levosimendan on the basis of the treatment plan of the control group. After treatment, the effective rate, left ventricular ejection fraction (LVEF), left ventricular end-diastolic volume (LVEDV), left ventricular end-systolic volume (LVESV), serum sST2 level, NT-proBNP level and the incidence of disease-related adverse reactions after treatment were compared between the two groups. Measurement data with normal distribution were expressed as xˉ± s, and the mean comparison between groups was performed by independent sample t test. Counting data were expressed as case(%), comparison between groups was performed by χ2 test. P<0.05 was considered statistically significant. Results:After treatment, the effective rate of the observation group was 97.47% (77/79), which was significantly higher than 82.28% (65/79) of the control group ( χ2=10.01, P=0.002); at the same time, the LVEF level of the observation group after intervention was (49.26±3.98)%, which was significantly higher than that of the control group (46.13±4.02)%, and the difference was statistically significant ( t=4.92, P<0.001), and the levels of LVEDV and LVESV in the observation group after intervention were (104.25±18.36)mL and (49.24±6.37)mL, respectively, which were significantly lower than (118.97±19.25)mL and (55.12±6.28)mL in the control group, and the differences were statistically significant ( t values were 4.92 and 5.84, respectively; all P<0.01). In addition, the levels of sST2 and NT-proBNP in the observation group after intervention were (37.25±15.48)μg/L and (825.37±86.24)ng/L, respectively, which were significantly lower than those in the control group (66.35±16.37)μg/L and (1136.24±121.75)ng/L, and the differences were statistically significant ( t values were 11.48 and 18.52, respectively; all P<0.001); the total incidence of adverse drug reactions in the observation group and the control group was 17.72% (14/79) and 18.90% (15/79), respectively, and the difference was not statistically significant ( χ2=0.04, P=0.837). Conclusion:The combination of levosimendan and dual antiplatelet therapy can effectively improve the efficacy of ischemic cardiomyopathy in heart failure, improve ventricular remodeling, and regulate sST2 and NT proBNP levels, with high application value.

The biodiversity of the mycobiome, an important component of the oral microbial community, and the roles of fungal-bacterial and fungal-immune system interactions in the pathogenesis of oral lichen planus (OLP) remain largely uncharacterized. In this study, we sequenced the salivary mycobiome and bacteriome associated with OLP. First, we described the dysbiosis of the microbiome in OLP patients, which exhibits lower levels of fungi and higher levels of bacteria. Significantly higher abundances of the fungi Candida and Aspergillus in patients with reticular OLP and of Alternaria and Sclerotiniaceae_unidentified in patients with erosive OLP were observed compared to the healthy controls. Aspergillus was identified as an "OLP-associated" fungus because of its detection at a higher frequency than in the healthy controls. Second, the co-occurrence patterns of the salivary mycobiome-bacteriome demonstrated negative associations between specific fungal and bacterial taxa identified in the healthy controls, which diminished in the reticular OLP group and even became positive in the erosive OLP group. Moreover, the oral cavities of OLP patients were colonized by dysbiotic oral flora with lower ecological network complexity and decreased fungal-Firmicutes and increased fungal-Bacteroidetes sub-networks. Third, several keystone fungal genera (Bovista, Erysiphe, Psathyrella, etc.) demonstrated significant correlations with clinical scores and IL-17 levels. Thus, we established that fungal dysbiosis is associated with the aggravation of OLP. Fungal dysbiosis could alter the salivary bacteriome or may reflect a direct effect of host immunity, which participates in OLP pathogenesis.
Adult ; Bacteria ; isolation & purification ; Case-Control Studies ; Dysbiosis ; complications ; microbiology ; Female ; Humans ; Lichen Planus, Oral ; complications ; microbiology ; Male ; Microbiota ; Middle Aged ; Mouth Mucosa ; microbiology ; Mycobiome ; Saliva ; microbiology